SLC5A2 and type 1 diabetes mellitus: Dapagliflozin is a potent, reversible, and selective inhibitor of (SGLT2), which is currently approved for type 2 diabetes treatment by the European Union; it is also the first SGLT2 inhibitor approved for using in type 1 diabetes (Dhillon, 2019; Paik and Blair, 2019).